A novel tumor suppressor, BATF2, can be silenced by factors in the tumor microenvironment, leading to a reduced immune ...

BATF2 is a new type of tumor suppressor that can be epigenetically silenced by high levels of glutamine in the tumor microenvironment Glutamine silences BATF2 and leads to a weakened immune response ...

Find out about TECregen's, a Basel-based company developing novel biologics designed to rejuvenate the thymus, “thymopoietics ...

A novel tumor suppressor, BATF2, can be silenced by factors in the tumor microenvironment, leading to a reduced immune response in five preclinical ...

Recent findings reveal Cornell prime dots can activate the immune system against melanoma, improving cancer immunotherapy ...

Company closed $22M financing to support randomized Phase 2b trial; IND cleared and study initiated; Interim results anticipated in late 2026; topline data expected in H2/2027 ...

A nano-sized medicine boosts the anti-cancer immune response and eradicates tumors in mice. Researchers at Washington University School of Medicine in St. Louis, working with colleagues at ...

The gut microbiome has been shown to influence tumor growth and contribute to therapeutic resistance. Scientists have ...

A novel tumor suppressor, BATF2, can be silenced by factors in the tumor microenvironment, leading to a reduced immune response in five preclinical models of head and neck cancer, according to ...

Janux Therapeutics develops intratumoral immuno-oncology therapies as nasdaq 100 index discussions highlight biotech ...

TECregen seed funding supports the development of thymus regeneration biologics designed to restore immune function and ...

Scientists have uncovered how a vitamin A metabolite can suppress anti-cancer immunity. Scientists at the Princeton University Branch of the Ludwig Institute for Cancer Research have uncovered new ...